These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 20661915)
1. Effective management of accelerated phase myelofibrosis with low-dose splenic radiotherapy. Pardanani A; Brown P; Neben-Wittich M; Tobin R; Tefferi A Am J Hematol; 2010 Sep; 85(9):715-6. PubMed ID: 20661915 [TBL] [Abstract][Full Text] [Related]
2. Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma. Ishibashi N; Maebayashi T; Aizawa T; Sakaguchi M; Abe O; Saito T; Tanaka Y Hematology; 2015 May; 20(4):203-7. PubMed ID: 25131182 [TBL] [Abstract][Full Text] [Related]
3. Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fraction radiation therapy. Neben-Wittich MA; Brown PD; Tefferi A Am J Hematol; 2010 Oct; 85(10):808-10. PubMed ID: 20799357 [TBL] [Abstract][Full Text] [Related]
4. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Mascarenhas J; Lu M; Li T; Petersen B; Hochman T; Najfeld V; Goldberg JD; Hoffman R Br J Haematol; 2013 Apr; 161(1):68-75. PubMed ID: 23330839 [TBL] [Abstract][Full Text] [Related]
5. [Splenic irradiation in the treatment of idiopathic myelofibrosis. Retrospective study of 14 cases]. Sciascia R; Mazza P; Tondi L Radiol Med; 1988; 76(1-2):87-90. PubMed ID: 3399713 [TBL] [Abstract][Full Text] [Related]
6. Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis. Song MK; Park BB; Uhm JE Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562644 [TBL] [Abstract][Full Text] [Related]
7. Radiotherapy for splenomegaly. Mod H; Prasiko G; Jha AK; Chaurasia PP; Srivastava R JNMA J Nepal Med Assoc; 2005; 44(159):97-9. PubMed ID: 16554863 [TBL] [Abstract][Full Text] [Related]
8. Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis. Guy A; Bidet A; Ling C; Caumont C; Boureau L; Viallard JF; Parrens M Virchows Arch; 2021 Oct; 479(4):755-764. PubMed ID: 33934231 [TBL] [Abstract][Full Text] [Related]
9. Repeated and preemptive palliative radiotherapy of symptomatic hepatomegaly in a patient with advanced myelofibrosis. Riesterer O; Gmür J; Lütolf U Onkologie; 2008 Jun; 31(6):325-7. PubMed ID: 18547974 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Martínez-Trillos A; Gaya A; Maffioli M; Arellano-Rodrigo E; Calvo X; Díaz-Beyá M; Cervantes F Ann Hematol; 2010 Dec; 89(12):1233-7. PubMed ID: 20567824 [TBL] [Abstract][Full Text] [Related]
11. The effects of hematopoietic stem cell transplant on splenic extramedullary hematopoiesis in patients with myeloproliferative neoplasm-associated myelofibrosis. Pizzi M; Gergis U; Chaviano F; Orazi A Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):96-104. PubMed ID: 27521149 [TBL] [Abstract][Full Text] [Related]
12. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. Tefferi A Am J Hematol; 2011 Dec; 86(12):1017-26. PubMed ID: 22086865 [TBL] [Abstract][Full Text] [Related]
13. Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt. Mishchenko E; Tefferi A Eur J Haematol; 2010 Sep; 85(3):192-9. PubMed ID: 20528907 [TBL] [Abstract][Full Text] [Related]
14. [Symptomatic irradiation therapy of the spleen in advanced osteomyelosclerosis]. Slanina J; Vondraczek A; Wannenmacher M Dtsch Med Wochenschr; 1986 Jul; 111(30):1144-50. PubMed ID: 2426078 [TBL] [Abstract][Full Text] [Related]
15. Splenic irradiation as palliative treatment for symptomatic splenomegaly due to secondary myelofibrosis: a multi-institutional experience. Pistevou-Gombaki K; Zygogianni A; Kantzou I; Kyrgias G; Mystakidou K; Kouvaris J; Klonizakis I; Tsirigotis P; Pappa V; Siakantari M; Eleftheriadis N; Georgakopoulos J; Sarris G; Kelekis N; Kouloulias V J BUON; 2015; 20(4):1132-6. PubMed ID: 26416067 [TBL] [Abstract][Full Text] [Related]
16. Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Koch CA; Li CY; Mesa RA; Tefferi A Mayo Clin Proc; 2003 Oct; 78(10):1223-33. PubMed ID: 14531481 [TBL] [Abstract][Full Text] [Related]
17. [Splenic extramedullary hematopoiesis in myelofibrosis. Pathogenetic considerations apropos of a personally studied case]. Piaserico PL; Piaserico GP Minerva Med; 1983 Oct; 74(39):2313-8. PubMed ID: 6657100 [TBL] [Abstract][Full Text] [Related]
18. Conventional cytogenetics in myelofibrosis: literature review and discussion. Hussein K; Van Dyke DL; Tefferi A Eur J Haematol; 2009 May; 82(5):329-38. PubMed ID: 19141119 [TBL] [Abstract][Full Text] [Related]
19. C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients. Wang X; Cho SY; Hu CS; Chen D; Roboz J; Hoffman R Exp Hematol; 2015 Feb; 43(2):100-9.e1. PubMed ID: 25461253 [TBL] [Abstract][Full Text] [Related]
20. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Kröger N; Thiele J; Zander A; Schwerdtfeger R; Kobbe G; Bornhäuser M; Bethge W; Schubert J; de Witte T; Kvasnicka HM; Exp Hematol; 2007 Nov; 35(11):1719-22. PubMed ID: 17976523 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]